ProKidney Corp. (PROK)
NASDAQ: PROK · Real-Time Price · USD
2.000
-0.010 (-0.50%)
At close: Feb 11, 2026, 4:00 PM EST
1.990
-0.010 (-0.50%)
After-hours: Feb 11, 2026, 7:01 PM EST
ProKidney Employees
ProKidney had 204 employees as of December 31, 2024. The number of employees increased by 41 or 25.15% compared to the previous year.
Employees
204
Change (1Y)
41
Growth (1Y)
25.15%
Revenue / Employee
$3,647
Profits / Employee
-$348,201
Market Cap
601.67M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 204 | 41 | 25.15% |
| Dec 31, 2023 | 163 | 76 | 87.36% |
| Dec 31, 2022 | 87 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 834 |
| MeiraGTx Holdings | 409 |
| REGENXBIO | 353 |
| Vor Biopharma | 154 |
| Gossamer Bio | 145 |
| Lexicon Pharmaceuticals | 103 |
| Keros Therapeutics | 82 |
| Design Therapeutics | 55 |
PROK News
- 11 days ago - ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably - Seeking Alpha
- 4 weeks ago - ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates - GlobeNewsWire
- 3 months ago - ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025 - GlobeNewsWire
- 3 months ago - ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference - GlobeNewsWire
- 4 months ago - ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025 - GlobeNewsWire
- 5 months ago - ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy - Seeking Alpha